Bøger af Sushil Sharma

The Charnolosome as a Novel Nanothereranostic Biomarker: Overcoming Future Challenges in Medicine provides an overview of the charnolosome and its potential as a biomarker of cell injury. Based on the author’s original discovery of the charnoly body in the developing, undernourished rat cerebellar Purkinje neurons, this book delves into the potential for utilizing this mitochondria and lysosomal-derived intracellular organelle as a nanotheranostic biomarker to prevent and cure various diseases. The book discusses the cellular, molecular, genetic, and epigenetic mechanisms of charnolosomes and charnolosome-derived nano-vesicles. It also investigates the molecular mechanisms underlying auto-inflammatory, autoimmune, and infectious diseases resulting from their compromised mitochondrial bioenergetics, and the potential use of the charnolosome in preventing and curing such conditions.

Nova Science Publishers now introduce an interesting book on research to help reduce global tobacco-related diseases in four volumes. Volume One describes general topics on nicotinism and the emerging role of electronic cigarettes; Volume Two describes basic molecular biology of nicotinism; Volume Three describes emerging biotechnology in nicotinism; and Volume Four describes chronic diseases associated with nicotinism and disease-specific-spatiotemporal (DSST) charnolosomics and charnolopharmacotherapeutics for the targeted, safe and effective personalized theranostics of nicotinism. The most interesting and unique feature of this book is that it introduces the original concept of disease-specific spatio-temporal (DSST) charnolosomics along with conventional omics (including genomics, proteomics, metabolomics, lipidomics, and metallomics) by employing combinatorial and correlative-bioinformatics to accomplish targeted, safe, and effective perosonalized theranostics of nicotinism. This book presents basic molecular biology and pharmacogenomics of nicotinism and the emerging role of e-cigarettes as an alternative to reduce tobacco cravings and related health risks, and to prevent second hand smoking-related health risks. The book illustrates specifically the novel concept of mitochondrial bioenergetics-based charnolopharmacotherapeutics for the clinical management of nicotinism with future prospects to minimize tobacco smoking behavior, and/or quit smoking with minimum withdrawal symptoms. This book presents recent knowledge and wisdom regarding more harmful aspects and limited therapeutic benefits of tobacco smoking through incineration or by vaping through e-cigarettes. The book is primarily for the health and well-being of highly vulnerable adolescents, who engage in drug seeking behavior, become victims of chronic tobacco addiction, and suffer from poor quality of life, early morbidity, and mortality. Moreover, tobacco exposure during intrauterine life can induce diversified embryopathies (such as abortion, stillbirth, sudden infant death syndrome, microcephaly, craniofacial abnormalities, growth retardation, ADHD, autism, and craniofacial abnormalities) in developing infants; and asthma, COPD, cancer, and infertility in adults. Hence, the primary goal is to minimize tobacco-induced early morbidity and mortality due to asthma, emphysema, cancer, heart attack, diabetes, obesity, infertility, major depressive disorders, schizophrenia, Alzheimers disease, and several other neurological and neuropsychiatric disorders.. Volume Four describes chronic diseases associated with nicotinism and novel disease-specific-spatiotemporal (DSST) charnolosomics and charnolopharmacotherapeutics for the targeted, safe and effective personalized theranostics of nicotinism. This volume is systematically presented in three sections. Sections One: Disease-Specific Nicotinism consists of eight chapters: Chapter One Nicotine and Stroke; Chapter Two Nicotine and Diabetes; Chapter Three Nicotine and Obesity; Chapter Four Nicotine and Parkinsons Disease; Chapter Five Nicotine and Alzheimers Disease; Chapter Six Nicotine and Schizophrenia; Chapter Seven Nicotine and Major Depressive Disorders; and Chapter Eight Nicotine and Cancer. Section Two: Charnolopharmacotherapeutics of Nicotinism consists of Chapter Nine, which describes the therapeutic potential of disease-specific spatiotmporal charnolopharmaceuticals in nicotinism, and Section Three highlights conclusions and future directions. Those interested in learning more about the basic molecular biology, molecular genetics, emerging biotechnology, diseases linked to nicotinism, and their possible prevention and cure will find this book interesting, exciting, motivating, and thought-provoking. This book is written primarily for biomedical students, researchers, scientist, professors, doctors, nurses, and any members of the general public interested in enhancing their existing knowledge and wisdom regarding the deleterious effects of both conventional as well as emerging e-cigarettes on human health and well-being, particularly among adolescents and young adults.

Nova Science Publishers now introduce an interesting book on research to help reduce global tobacco-related diseases in four volumes. Volume One describes general topics on nicotinism and the emerging role of electronic cigarettes; Volume Two describes basic molecular biology of nicotinism; Volume Three describes emerging biotechnology in nicotinism; and Volume Four describes chronic diseases associated with nicotinism and disease-specific-spatiotemporal (DSST) charnolosomics and charnolopharmacotherapeutics for the targeted, safe and effective personalized theranostics of nicotinism. This book is written primarily for readers interested in learning more about the basic molecular biology, recent biotechnology, and molecular genetics for diseases linked to nicotinism as well as their possible prevention and cure. A novel disease-specific spatiotemporal charnolosomics along with conventional omics (genomics, proteomics, metabolomics, lipidomics, and metallomics) with correlative and combinatorial bioinformatic analysis is proposed for the first time to accomplish targeted, safe, and effective personalized theranostics of nicotinism for a better quality of life. This book is written primarily for the health and well-being of highly vulnerable adolescents, who engage in drug seeking behavior (particularly tobacco and alcohol), become victims of chronic addiction, and suffer from poor quality of life, early morbidity, and mortality. Moreover, nicotine exposure during intrauterine life can induce diversified embryopathies (such as abortion, stillbirth, sudden infant death syndrome, microcephaly, craniofacial abnormalities, growth retardation, ADHD, autism, and craniofacial abnormalities) in developing infants; likewise, asthma, COPD, cancer, and infertility occurs in adults. The primary goal is to minimize nicotine-induced early morbidity and mortality due to asthma, emphysema, cancer, heart attack, diabetes, obesity, infertility, major depressive disorders, schizophrenia, Alzheimers disease, and several other neurological and neuropsychiatric disorders, which are elegantly described in this book. Volumes Three describes emerging biotechnology in nicotinism in three sections: Section One illustrates emerging biotechnology in nicotinism, consisting of eight chapters: Chapter One Evaluation of Nicotinism by Flow Cytometry and Other Emerging Biotechnology (Molecular Neuroimaging); Chapter Two Mitochondrial Bioenergetics and Immunophenotyping of Nicotinism (A Flow Cytometric Analysis of Charnoly Body Dynamics in Nicotinism); Chapter Three Flow Cytometric Analysis of Charnolophagy and Charnolosome Exocytosis/Endocytosis in Nicotinism; Chapter Four Mass Spectrometric Analysis of Nicotine and Nicotinism; Chapter Five Pet Neuroimaging in Nicotinism (With Special Reference to Nicotinic Acetyl Choline Receptor Imaging); Chapter Six Multimodality Molecular Neuroimaging in Nicotinism; Chapter Seven Personalized Theranostic Potential of Nanomedicine in Nicotinism; and Chapter Eight Mitochondrial Bioenergetics and Charnolopharmacotherapeutics in Nicotinism. Section Two: Disease-Specific Personalized Theranostics of Nicotinism highlights disease-specific personalized theranostics of nicotinism in Chapter Nine, and Section Three: Clinical Management of Nicotinism details harmful aspects and therapeutic benefits of nicotine in Chapter Ten. While each volume will serve as a textbook for biomedical students and as a reference book for researchers, scientists, doctors, and professors, all four of the volumes systematically will certainly enhance the existing knowledge and wisdom regarding nicotinism and drug addiction in general. It is envisaged that readers (researchers, doctors, nurses, teachers, students (particularly high school and college students) and the general public will enjoy learning the most recent and novel personalized theranostic approaches currently being implemented in this clinically-significant discipline by carefully going through the most interesting and thought-provoking contents of this book.

Nova Science Publishers, New York, U.S.A has now released Personalized Medicine (Beyond PET Biomarkers), which is an extension of the authors recently published book Progress in PET Radiopharmaceuticals: Quality Control and Theranostics. In addition to recently-developed clinically-significant PET-RPs as biomarkers, this book describes various other emerging biotechnologies including: genomic medicine, nanotechnology, novel molecular biomarkers, and noninvasive imaging biotechnologies for early theranostics and personalised patient care, with minimum or no adverse effects. New therapeutic interventions including gene and cell therapies, pharmacogenomics, next generation sequencing, genome-wide association studies, proteomics, metabolomics, bioinformatics, systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigations and clinical trials, pharmacovigilance, pharmacoepidemiology, and population pharmacology are some of the most significant disciplines of predictive, precision, and personalised medicine (PM) as described in this book. More specifically, different sub-specialties of omics biotechnology including: genomic, proteomic, glycomic, lipidomic, metabolomics, metalomic, and microRNA biomarkers are described to accomplish early and personalised theranostics of chronic illnesses with currently limited therapeutic options and success. Recent advances in nanotechnology and novel biomarkers to accomplish personalised theranostics of chronic diseases including, but not limited to: cancer, fetal alcohol syndrome, Alzheimers disease, Parkinsons disease, vascular dementia, amyotrophic lateral sclerosis, and multiple sclerosis. Usually, nanoparticles (NPs) are trapped in the reticuloendothelial system (RES) comprising the lungs, liver, and spleen. To prevent their entry into the RES system and enhance drug targeting, stealth property of polyethylene glycol (PEG) as a covalent linker is utilised. However, pegylation may reduce the biological activity of the antibody or other labile molecule attached to NPs. Therefore, positively-charged chitosans and negatively charged alginates have been developed. Liposomal encapsulated Doxorubicin (Adriamycin) was approved in the early seventies for the treatment of breast cancer. In addition, enhanced permeability and retention (EPR) property of newly synthesised micro vessels of a hyper proliferating tumor is utilised to selectively invade the cancer stem cells is intricately described. Various noninvasive in-vivo imaging technologies including computerised tomography (CT), magnetic resonance imaging (MRI) along with magnetic-resonance spectroscopic (MRS) capability, single photon emission tomography (SPECT), positron emission tomography (PET), ultra sound alone or as hybrid images to obtain precise 5D anatomical landmarks, regional physiology, and biochemistry of the human body organs at cellular, molecular, and genetic level in health and disease are described. The book also describes in-vitro methods to acquire images of tissues and cells in culture employing digital infrared imaging, digital fluorescence microscopic, confocal microscopic, and fluorescence resonance transfer (FRET) resonance imaging for detecting apoptosis and/or necrosis at the cellular, molecular and genetic level. This timely-released manuscript will attract basic scientists, researchers, and physicians interested in further developing the emerging concept of personalised medicine (PM), and will serve as a textbook for Masters, M.D., and Ph. D students, and a reference book for doctors, professors, basic researchers, scientists, and general public. The author has explained recently-discovered novel biomarkers for the personalised diagnosis and treatment of cancer, cardiovascular diseases, neurodegenerative diseases, and other chronic inflammatory diseases such as asthma, COPD, cystic fibrosis, migraine, and rheumatoid arthritis to accomplish the long quested goal of evidence-based personalised theranostics (EBPT). Recently-discovered disease-specific biomarkers can be successfully employed alone or in combination for the personalised treatment of chronic multidrug-resistant illnesses. Particularly, progressive neurodegenerative diseases such as fetal alcohol syndrome, Parkinsons disease, drug addiction, Alzheimers disease, vascular dementia, amyotrophic lateral sclerosis, and demyelinating relapse and remission multiple sclerosis (RRMS) are described in detail because personalised treatment of these devastating diseases is currently a significant challenge. There are several other chronic drug resistant pro-inflammatory and infectious diseases, which could not be covered in sufficient detail owing to the lack of expertise, time, and limited space allocated to write this dedicated and clinically significant book. The author apologises to the entire global scientific community for his own ignorance, and humbly requests readers to go through the books interesting and most recent contents to enhance their basic knowledge regarding personalised medicine beyond PET biomarkers, which is one of the most demanding disciplines of modern medicine.

The author was motivated to write this important book because currently there is no systematically-written document on the ZIKV disease, which could serve at this crucial moment as a textbook for medical students, physicians, nurses, and other healthcare providers as well as a reference book for basic researchers, professors, and the general public. The original concept of ZIKV-Charnolopathy due to compromised mitochondrial bioenergetics in highly vulnerable (neural progenitor cells, spermatocytes, oocytes etc.) cells and its amelioration by physiological and/or pharmacological interventions is based on years of research experience. This book describes unique organ and disease-specific Charnoly body (CB) inhibitors, charnolophagy inducers, CB sequestration inhibitors, and chanolophagosome stabilisers as promising charnolopharmacotherapeutics. They are meant to aid in the prevention and treatment of the ZIKV-linked diversified spectrum of neurodevelopmental anomalies (embryopathies) in newborn infants and Guillain Barre Syndrome (GBS) in adults. Clinical management of ZIKV-induced GBS employing IV immunoglobulin and plasmapheresis (plasma exchange) is also described.